Tech Company Financing Transactions
ABK Biomedical Funding Round
ABK Biomedical closed a $35 million Series D venture capital round on 10/14/2025. Investors included J.P. Morgan, Eight Roads and F-Prime Capital.
Transaction Overview
Company Name
Announced On
10/14/2025
Transaction Type
Venture Equity
Amount
$35,000,000
Round
Series D
Investors
Proceeds Purpose
The company intends to use the funds for ongoing clinical operations, prepare for the commercialization of Eye90 microspheres®, and drive further product innovation and development. Additional funds will be used to increase the scale and scope of its manufacturing and supply chain operations to support Eye90 microspheres commercialization well into the future.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
155 Chain Lake Dr. 32
Halifax NS, B3S 1B3
Canada
Halifax NS, B3S 1B3
Canada
Phone
Website
Email Address
Overview
ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Mangano
Chief Financial Officer
Michael Tyson
Chief Medical Officer
Robert Abraham
VP - Bus. Development
Gary Donofrio
VP - Operations
Marc Gregoire
VP - Regulatory Affairs
David Dobrowski
Browse more venture capital transactions:
Prev: 10/14/2025: Basis Theory venture capital transaction
Next: 10/14/2025: Caracol venture capital transaction
Share this article
Where The Data Comes From
We record all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs